Prognostic Value of Circulating Tumour Cells in Limited-stage Small-cell Lung Cancer: Analysis of the Concurrent Once-daily Versus Twice-daily Radiotherapy (CONVERT) Randomised Controlled Trial

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2019 Apr 26

PMID 31020334

Citations 37

Authors

R Y Tay

F Fernandez-Gutierrez

V Foy

K Burns

J Pierce

K Morris

L Priest

J Tugwood

L Ashcroft

C R Lindsay

C Faivre-Finn

C Dive

F Blackhall

Affiliations

Soon will be listed here.

Abstract

Background: The clinical significance of circulating tumour cells (CTCs) in limited-stage small-cell lung cancer (LS-SCLC) is not well defined. We report a planned exploratory analysis of the prevalence and prognostic value of CTCs in LS-SCLC patients enrolled within the phase III randomised CONVERT (concurrent once-daily versus twice-daily chemoradiotherapy) trial.

Patients And Methods: Baseline blood samples were enumerated for CTCs using CellSearch in 75 patients with LS-SCLC who were enrolled in the CONVERT trial and randomised between twice- and once-daily concurrent chemoradiation. Standard statistical methods were used for correlations of CTCs with clinical factors. Log-rank test and Cox regression analyses were applied to establish the associations of 2, 15 and 50 CTC thresholds with progression-free survival (PFS) and overall survival (OS). An optimal CTC count threshold for LS-SCLC was established.

Results: CTCs were detected in 60% (45/75) of patients (range 0-3750). CTC count thresholds of 2, 15 and 50 CTCs all significantly correlate with PFS and OS. An optimal CTC count threshold in LS-SCLC was established at 15 CTCs, defining 'favourable' and 'unfavourable' prognostic risk groups. The median OS in <15 versus ≥15 CTCs was 26.7 versus 5.9 m (P = 0.001). The presence of ≥15 CTCs at baseline independently predicted ≤1 year survival in 70% and ≤2 years survival in 100% of patients.

Conclusion: We report the prognostic value of baseline CTC count in an exclusive LS-SCLC population at thresholds of 2, 15 and 50 CTCs. Specific to LS-SCLC, ≥15 CTCs was associated with worse PFS and OS independent of all other factors and predicted ≤2 years survival. These results may improve disease stratification in future clinical trial designs and aid clinical decision making.

Trial Registration: ClinicalTrials.gov identifier: NCT00433563.

Citing Articles

RHBDF1 modulates cisplatin sensitivity of small cell lung cancer through YAP1/Smad2 signaling pathway.

Wang L, Qi L, Huang X, Feng X, Gan J, Zhang J Heliyon. 2024; 10(13):e33454.

PMID: 39027514 PMC: 11254170. DOI: 10.1016/j.heliyon.2024.e33454.

Advances in the role of circulating tumor cell heterogeneity in metastatic small cell lung cancer.

Wang Q, Tan L Cancer Innov. 2024; 3(2):e98.

PMID: 38946931 PMC: 11212323. DOI: 10.1002/cai2.98.

Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?.

Fasano R, Serrati S, Rafaschieri T, Longo V, Di Fonte R, Porcelli L Biomolecules. 2024; 14(4).

PMID: 38672414 PMC: 11048475. DOI: 10.3390/biom14040396.

The integrated on-chip isolation and detection of circulating tumour cells.

Abusamra S, Barber R, Sharafeldin M, Edwards C, Davis J Sens Diagn. 2024; 3(4):562-584.

PMID: 38646187 PMC: 11025039. DOI: 10.1039/d3sd00302g.

Single-cell low-pass whole genome sequencing accurately detects circulating tumor cells for liquid biopsy-based multi-cancer diagnosis.

Shen X, Dai J, Guo L, Liu Z, Yang L, Gu D NPJ Precis Oncol. 2024; 8(1):30.

PMID: 38321112 PMC: 10847465. DOI: 10.1038/s41698-024-00520-1.

References

Sastre J, Maestro M, Puente J, Veganzones S, Alfonso R, Rafael S . Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol. 2008; 19(5):935-8. DOI: 10.1093/annonc/mdm583. View

Lucci A, Hall C, Lodhi A, Bhattacharyya A, Anderson A, Xiao L . Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012; 13(7):688-95. DOI: 10.1016/S1470-2045(12)70209-7. View

Hayes D, Cristofanilli M, Budd G, Ellis M, Stopeck A, Miller M . Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006; 12(14 Pt 1):4218-24. DOI: 10.1158/1078-0432.CCR-05-2821. View

Hodgkinson C, Morrow C, Li Y, Metcalf R, Rothwell D, Trapani F . Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014; 20(8):897-903. DOI: 10.1038/nm.3600. View

Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A . Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24(28):4539-44. DOI: 10.1200/JCO.2005.04.4859. View

Belani C, Dahlberg S, Rudin C, Fleisher M, Chen H, Takebe N . Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016; 122(15):2371-8. PMC: 4956531. DOI: 10.1002/cncr.30062. View

Pignon J, Arriagada R, Ihde D, Johnson D, Perry M, Souhami R . A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992; 327(23):1618-24. DOI: 10.1056/NEJM199212033272302. View

Carter L, Rothwell D, Mesquita B, Smowton C, Leong H, Fernandez-Gutierrez F . Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nat Med. 2016; 23(1):114-119. DOI: 10.1038/nm.4239. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

10.

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009; 20(7):1223-9. DOI: 10.1093/annonc/mdn786. View

11.

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A . Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017; 18(8):1116-1125. PMC: 5555437. DOI: 10.1016/S1470-2045(17)30318-2. View

12.

Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S . Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009; 15(22):6980-6. DOI: 10.1158/1078-0432.CCR-09-1095. View

13.

Hou J, Greystoke A, Lancashire L, Cummings J, Ward T, Board R . Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009; 175(2):808-16. PMC: 2716975. DOI: 10.2353/ajpath.2009.090078. View

14.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

15.

Kraan J, Sleijfer S, Strijbos M, Ignatiadis M, Peeters D, Pierga J . External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study. Cytometry B Clin Cytom. 2011; 80(2):112-8. DOI: 10.1002/cyto.b.20573. View

16.

Pietanza M, Waqar S, Krug L, Dowlati A, Hann C, Chiappori A . Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol. 2018; 36(23):2386-2394. PMC: 6085179. DOI: 10.1200/JCO.2018.77.7672. View

17.

Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B . Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920-8. DOI: 10.1158/1078-0432.CCR-06-1695. View

18.

Igawa S, Gohda K, Fukui T, Ryuge S, Otani S, Masago A . Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett. 2014; 7(5):1469-1473. PMC: 3997694. DOI: 10.3892/ol.2014.1940. View

19.

Cristofanilli M, Hayes D, Budd G, Ellis M, Stopeck A, Reuben J . Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005; 23(7):1420-30. DOI: 10.1200/JCO.2005.08.140. View

20.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005; 93(4):387-91. PMC: 2361579. DOI: 10.1038/sj.bjc.6602678. View